By using our website, you agree to the use of our cookies.


Monthly summary – April 2023

By Karin May 5, 2023

Strong earnings beat weak regional banks! Following the collapse of Silicon Valley Bank and Credit Suisse in March, market action was dominated by fears of a full-blown bank crisis not seen since 2008. As these fears successively subsided, even though problems remained for some regional banks such as First Republic, investors in April choose to […]

Monthly summary – March 2023

By Karin April 6, 2023

During the latter part of 2022 and in the first two months of this year, bank shares performed strongly on the perception that higher interest rates generally improve bank earnings. However, that view came to a screeching halt when Silicon Valley Bank went under in a matter of a few days and was taken over […]

Monthly summary – February 2023

By Karin March 8, 2023

Inflation and war once again made the headlines in February. Throughout a dismal 2022, when investors had to accustom themselves to the horrors of war and a steep increase in the price of money, their exposure to risk assets was successively reduced. With a relatively low participation level at the end of the year, the […]

Monthly summary – January 2023

By Karin February 8, 2023

MONTHLY SUMMARY What a difference a month makes! While December posted a large drawdown in stock prices, January saw one of the strongest starts of a year ever. The widespread pessimism and hence relatively low equity exposures at the end of 2022 quickly changed into a risk-on sentiment, much to the chagrin of many large […]

Monthly summary – December 2022

By Karin January 6, 2023

Interest rates, recession risks and earnings downgrades weighed down on investor sentiment in December. The much-anticipated Christmas rally did not materialize and equities fell during the month, closing out 2022 as the worst year since the global financial crisis of 2008. As had been the case for most of the year, the drawdown was once […]

Rhenman & Partners strengthens its investment team with a biopharma analyst

By Karin December 20, 2022

Rhenman & Partners hires Amennai Beyeen as biopharma analyst. Amennai will have a particular focus on biopharma companies and the development of new drugs and treatments. He will be working closely with all colleagues of Rhenman & Partners’ five-person investment team, all based in the firm’s Stockholm office. Most recently Amennai comes from Novartis, where […]

Summary – November 2022

By Karin December 8, 2022

Rate hikes and their impact on economic growth and earnings were the factors that defined November. The aggressive actions of central banks so far this year have probably influenced capital markets more than anything else, including the war in Ukraine. Having been caught wrongfooted by persistently high inflation numbers, the Federal Reserve and its counterparties […]

Summary – October 2022

By Karin November 14, 2022

Following a poor September, capital markets experienced a strong October. The US Dow Jones Index posted its best October-month ever. Inflation numbers and thus interest rate hikes by central banks continued to take center stage. Fears that aggressive hikes would lead to a recession were mitigated by strong labor statistics, especially in the US. Value […]

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

By Karin September 30, 2022

Rhenman & Partners Asset Management AB appoints Teresa Isele as new CEO. Co-founder and current CEO Göran Nordström retires at the age of 69. Most recently Teresa comes from the role as CEO at Swedsec, which provides a licensing system for employees within the Swedish financial services industry. Teresa has previously held roles as acting […]

Visa fler nyheter